Prospective comparative study of ¹⁸F-sodium fluoride PET/CT and planar bone scintigraphy for treatment response assessment of bone metastases in patients with prostate cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–1403.
   PubMed Web of Science ®Google Scholar
• Pilon D, Queener M, Lefebvre P, et al. Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer. J Med Econ. 2016;19:777–784.
   PubMed Web of Science ®Google Scholar
• Sanyal C, Aprikian AG, Cury FL, et al. Management of localized and advanced prostate cancer in Canada: a lifetime cost and quality-adjusted life-year analysis. Cancer. 2016;122:1085–1096.
   PubMed Web of Science ®Google Scholar
• Savage P, Mahmoud S. Development and economic trends in cancer therapeutic drugs: a 5-year update 2010–2014. Br J Cancer. 2015;112:1037–1041.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65:124–137.
   PubMed Web of Science ®Google Scholar
• Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate cancer, version 1.2016. J Natl Compr Canc Netw. 2016;14:19–30.
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Pond GR, Armstrong AJ, et al. Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. BJU Int. 2014;114:E25–E31.
   PubMed Web of Science ®Google Scholar
• Zacho HD, Manresa JA, Mortensen JC, et al. Observer agreement and accuracy in the evaluation of bone scans in newly diagnosed prostate cancer. Nucl Med Commun. 2015;36:445–451.
   PubMed Web of Science ®Google Scholar
• Fonager RF, Zacho HD, Albertsen S, et al. Observer agreement of treatment responses on planar bone scintigraphy in prostate cancer patients: importance of the lesion assessment method. Nucl Med Commun. 2017;38:215–221.
   PubMed Web of Science ®Google Scholar
• Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630–642.
   PubMed Web of Science ®Google Scholar
• Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71:618–629.
   PubMed Web of Science ®Google Scholar
• Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177:2106–2131.
   PubMed Web of Science ®Google Scholar
• Apolo AB, Lindenberg L, Shih JH, et al. Prospective study evaluating Na18F PET/CT in predicting clinical outcomes and survival in advanced prostate cancer. J Nucl Med. 2016;57:886–892.
   PubMed Web of Science ®Google Scholar
• Cook G Jr, Parker C, Chua S, et al. 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin). EJNMMI Res. 2011;1:4.
   PubMed Web of Science ®Google Scholar
• Kairemo K, Joensuu T. Radium-223-dichloride in castration resistant metastatic prostate cancer-preliminary results of the response evaluation using F-18-Fluoride PET/CT. Diagnostics (Basel). 2015;5:413–427.
   PubMedGoogle Scholar
• Fonager RF, Zacho HD, Langkilde NC, et al. (18)F-fluoride positron emission tomography/computed tomography and bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancer patients: study protocol for a multicentre, diagnostic test accuracy study. BMC Cancer. 2016;16:10.
   PubMed Web of Science ®Google Scholar
• Van den Wyngaert T, Strobel K, Kampen WU, et al. The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging. 2016;43:1723–1738.
   PubMed Web of Science ®Google Scholar
• Beheshti M, Mottaghy FM, Payche F, et al. (18)F-NaF PET/CT: EANM procedure guidelines for bone imaging. Eur J Nucl Med Mol Imaging. 2015;42:1767–1777.
   PubMed Web of Science ®Google Scholar
• Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988;61:195–202.
   PubMed Web of Science ®Google Scholar
• Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461–3467.
   PubMed Web of Science ®Google Scholar
• Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148–1159.
   PubMed Web of Science ®Google Scholar
• Morris MJ, Autio KA, Basch EM, et al. Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable? Semin Oncol. 2013;40:375–392.
   PubMed Web of Science ®Google Scholar
• Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402–1418.
   PubMed Web of Science ®Google Scholar
• Hillner BE, Siegel BA, Hanna L, et al. Impact of 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry. J Nucl Med. 2014;55:574–581.
   PubMed Web of Science ®Google Scholar
• Hillner BE, Siegel BA, Hanna L, et al. Impact of (18)F-Fluoride PET on intended management of patients with cancers other than prostate cancer: results from the National Oncologic PET Registry. J Nucl Med. 2014;55:1054–1061.
   PubMed Web of Science ®Google Scholar
• Even-Sapir E, Metser U, Mishani E, et al. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287–297.
   PubMed Web of Science ®Google Scholar
• Fonager RF, Zacho HD, Langkilde NC, et al. Diagnostic test accuracy study of (18)F-sodium fluoride PET/CT, (99m)Tc-labelled diphosphonate SPECT/CT, and planar bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancer. Am J Nucl Med Mol Imaging. 2017;7:218–227.
   PubMed Web of Science ®Google Scholar
• Lofgren J, Mortensen J, Rasmussen SH, et al. A Prospective Study Comparing (99m)Tc-Hydroxyethylene-Diphosphonate Planar Bone Scintigraphy and Whole-Body SPECT/CT with (18)F-Fluoride PET/CT and (18)F-Fluoride PET/MRI for Diagnosing Bone Metastases. J Nucl Med. 2017;58:1778–1785.
   PubMed Web of Science ®Google Scholar
• Minamimoto R, Loening A, Jamali M, et al. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer. J Nucl Med. 2015;56:1862–1868.
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–433.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–148.
   PubMed Web of Science ®Google Scholar
• Nome R, Hernes E, Bogsrud TV, et al. Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223. Scand J Urol. 2015;49:211–217.
   PubMed Web of Science ®Google Scholar
• Anand A, Morris MJ, Larson SM, et al. Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide. EJNMMI Res. 2016;6:23.
   PubMed Web of Science ®Google Scholar
• Mitsui Y, Shiina H, Yamamoto Y, et al. Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer. BJU Int. 2012;110:E628–E634.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Shah S, Efstathiou E, et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011;17:4854–4861.
   PubMed Web of Science ®Google Scholar
• Morris MJ, Molina A, Small EJ, et al. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. J Clin Oncol. 2015;33:1356–1363.
   PubMed Web of Science ®Google Scholar
• Cook GJ, Fogelman I. Detection of bone metastases in cancer patients by 18F-fluoride and 18F-fluorodeoxyglucose positron emission tomography. Q J Nucl Med 2001;45:47–52.
   PubMedGoogle Scholar
• Weisman A, Harmon S, Perk T, et al. WE-FG-202-05: quantification of bone flare on [F-18] NaF PET/CT in metastatic prostate cancer. Med Phys. 2016;43:3827–3827.
   Web of Science ®Google Scholar
• Harmon SA, Perk T, Lin C, et al. Quantitative assessment of early [(18)F]sodium fluoride positron emission tomography/computed tomography response to treatment in men with metastatic prostate cancer to bone. J Clin Oncol. 2017;35:2829–2837.
   PubMed Web of Science ®Google Scholar
• Lindgren Belal S, Sadik M, Kaboteh R, et al. 3D skeletal uptake of (18)F sodium fluoride in PET/CT images is associated with overall survival in patients with prostate cancer. EJNMMI Res. 2017;7:15.
   PubMed Web of Science ®Google Scholar